Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Terminated 3Completed 3Active not recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Head & Neck 1Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Lung Neoplasms 1

Interventions

Carboplatin 158Pemetrexed 135Cisplatin 115pembrolizumab 99Docetaxel 94Paclitaxel 89Gemcitabine 63Erlotinib Hydrochloride 60Radiotherapy 55Nivolumab 55Bevacizumab 46Etoposide 42atezolizumab 33Radiosurgery 33durvalumab 28Cyclophosphamide 22Vinorelbine 21Ipilimumab 21Radiation 20Taxes 17130-nm albumin-bound paclitaxel 17Albumin-Bound Paclitaxel 16Gefitinib 14Irinotecan 13Drug Therapy 13osimertinib 12avelumab 12Magnetic Resonance Spectroscopy 12Dexamethasone 12Cetuximab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × nazartinib × Thoracic × Clear all
NCT03292133 2025-06-10

A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer

Massachusetts General Hospital

Phase 2 Terminated
11 enrolled 10 charts
Thoracic

Lung Neoplasms

NCT02335944 2023-06-18

Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.

Novartis

Phase 1/2 Terminated
177 enrolled 48 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02323126 2022-02-28

Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer

Novartis

Phase 2 Terminated
64 enrolled 28 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡